文献速递慢性肾脏病

维生素K2补充未能改善CKD患者血管僵硬度:K4Kidneys随机对照试验

Vitamin K Supplementation to Improve Vascular Stiffness in CKD: The K4Kidneys Randomized Controlled Trial.
PubMed 文献 · J Am Soc Nephrol · 2020-08-13

本研究为平行组双盲随机对照试验,纳入159例CKD 3b-4期患者,随机接受口服维生素K2 400μg每日一次或安慰剂治疗一年。主要结局为12个月时颈-股脉搏波速度的组间校正差异,结果未发现维生素K2对血管僵硬度或其他血管健康指标有改善作用。

要点

  • CKD 3b-4期患者每日补充维生素K2 400μg一年,未改善脉搏波速度。
  • 次级结局如增强指数、血压、BNP及体能均无组间差异。
  • 更新荟萃分析未显示维生素K补充对血管僵硬度或钙化有获益。

核心结论

  • 在CKD 3b-4期患者中,每日口服维生素K2 400μg持续一年未改善血管僵硬度或其他血管健康指标。

研究设计与样本

  • 平行组、双盲、随机对照试验,纳入年龄≥18岁、CKD 3b或4期(eGFR 15-45 ml/min per 1.73 m2)患者159例,随机分为维生素K2组80例和安慰剂组79例,每日口服400μg维生素K2或安慰剂一次,持续一年。

主要发现

  • 12个月时脉搏波速度组间校正差异无统计学意义。
  • 12个月时增强指数、血压、B型利钠肽及体能均无组间差异。
  • 更新荟萃分析显示维生素K补充对血管僵硬度或血管钙化指标无影响。

临床怎么用

  • 对于CKD 3b-4期患者,不推荐常规补充维生素K2以改善血管僵硬度或降低血管风险。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vascular calcification, a risk factor for cardiovascular disease, is common among patients with CKD and is an independent contributor to increased vascular stiffness and vascular risk in this patient group. Vitamin K is a cofactor for proteins involved in prevention of vascular calcification. Whether or not vitamin K supplementation could improve arterial stiffness in patients with CKD is unknown. METHODS: To determine if vitamin K supplementation might improve arterial stiffness in patients in CKD, we conducted a parallel-group, double-blind, randomized trial in participants aged 18 or older with CKD stage 3b or 4 (eGFR 15-45 ml/min per 1.73 m2). We randomly assigned participants to receive 400 μg oral vitamin K2 or matching placebo once daily for a year. The primary outcome was the adjusted between-group difference in carotid-femoral pulse wave velocity at 12 months. Secondary outcomes included augmentation index, abdominal aortic calcification, BP, physical function, and blood markers of mineral metabolism and vascular health. We also updated a recently published meta-analysis of trials to include the findings of this study. RESULTS: We included 159 randomized participants in the modified intention-to-treat analysis, with 80 allocated to receive vitamin K and 79 to receive placebo. Mean age was 66 years, 62 (39%) were female, and 87 (55%) had CKD stage 4. We found no differences in pulse wave velocity at 12 months, augmentation index at 12 months, BP, B-type natriuretic peptide, or physical function. The updated meta-analysis showed no effect of vitamin K supplementation on vascular stiffness or vascular calcification measures. CONCLUSIONS: Vitamin K2 supplementation did not improve vascular stiffness or other measures of vascular health in this trial involving individuals with CKD. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Vitamin K therapy to improve vascular health in patients with chronic kidney disease, ISRCTN21444964 (www.isrctn.com).

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Witham MD, Lees JS, White M, et al. Vitamin K Supplementation to Improve Vascular Stiffness in CKD: The K4Kidneys Randomized Controlled Trial. J Am Soc Nephrol. 2020. PMID: 32817311. doi:10.1681/ASN.2020020225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。